Loading
companiesCompany
Atara Biotherapeutics
Atara Biotherapeutics is the Californian company behind Ebvallo, the first approved off-the-shelf T-cell therapy, which treats Epstein-Barr virus lymphoma after transplant using T cells from healthy donors.
Also called: Atara Biotherapeutics, Inc.NASDAQ:ATRA
Overview
Atara Biotherapeutics develops allogeneic Epstein-Barr virus-specific T-cell therapies. Tabelecleucel (Ebvallo), made from banked donor T cells matched by HLA, was approved in the European Union in December 2022 and by the FDA in 2025 for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease; Pierre Fabre holds worldwide commercial rights. Atara's EBV-targeted CAR-T programme ATA3219 for lymphoma and lupus was paused in 2025 as the company restructured.
Headquarters
Thousand Oaks, California, US
Scorecard
All companies#276of 1244 companies, score 16
- approved products +6
- modalities +2
- regions +1
- registry trials +7
1 approved, 0 in phase 3, 0 earlier, 0 targets, 11 registry studies. Formula on the scorecards page.
Type
Cell therapy · NASDAQ:ATRA
Stage
Public
Website
Founded
2012
ApprovedCell therapy: allogeneic off-the-shelf Epstein-Barr virus-specific T cells
Tabelecleucel is a bank of donor T cells trained against Epstein-Barr virus, approved in Europe in 2022 as the first off-the-shelf T-cell therapy, for EBV-driven lymphoma after transplant when rituximab has failed.
drugs
ApprovedCell therapy: allogeneic off-the-shelf Epstein-Barr virus-specific T cells